产品
编 号：F085603
分子式：C22H19Br2FN2O
分子量：506.21
分子式：C22H19Br2FN2O
分子量：506.21
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1235481-90-9
产品详情
生物活性：
P7C3-A20 is a derivative of P7C3 with potent proneurogenic and neuroprotective activity. P7C3-A20 exerts an antidepressant-like effect. P7C3-A20 can cross the blood-brain barrier and therefore has the potential for brain injury treatment.
体内研究：
P7C3-A20 (5-10?mg/kg; intraperitoneal injection; daily; for 7 days; Sprague-Dawley rats)可减少梗塞体积；在 HI 模型大鼠中逆转皮质和海马体中的细胞损失并改善运动功能而不引起神经毒性。P7C3-A20 通过激活 PI3K/AKT/GSK3β 信号通路防止 HI 诱导的神经元损伤。Animal Model:Sprague-Dawley rats (200-250 g) induced hypoxic-ischemic (HI) injury
Dosage:5?mg/kg, 10?mg/kg
Administration:Intraperitoneal injection; daily; for 7 days
Result:Reduced infarct volume; reversed cell loss in the cortex and hippocampus and improved motor function without causing neurotoxicity.
体外研究：
P7C3-A20 (10-100 μM; 8 hours; PC12 cells) 处理可减轻 PC12 细胞中氧-葡萄糖剥夺 (OGD) 诱导的细胞毒性。P7C3-A20 (40-100 μM; 8 hours; PC12 cells) 处理可减轻 OGD 诱导的 PC12 细胞凋亡。
P7C3-A20 is a derivative of P7C3 with potent proneurogenic and neuroprotective activity. P7C3-A20 exerts an antidepressant-like effect. P7C3-A20 can cross the blood-brain barrier and therefore has the potential for brain injury treatment.
体内研究：
P7C3-A20 (5-10?mg/kg; intraperitoneal injection; daily; for 7 days; Sprague-Dawley rats)可减少梗塞体积；在 HI 模型大鼠中逆转皮质和海马体中的细胞损失并改善运动功能而不引起神经毒性。P7C3-A20 通过激活 PI3K/AKT/GSK3β 信号通路防止 HI 诱导的神经元损伤。Animal Model:Sprague-Dawley rats (200-250 g) induced hypoxic-ischemic (HI) injury
Dosage:5?mg/kg, 10?mg/kg
Administration:Intraperitoneal injection; daily; for 7 days
Result:Reduced infarct volume; reversed cell loss in the cortex and hippocampus and improved motor function without causing neurotoxicity.
体外研究：
P7C3-A20 (10-100 μM; 8 hours; PC12 cells) 处理可减轻 PC12 细胞中氧-葡萄糖剥夺 (OGD) 诱导的细胞毒性。P7C3-A20 (40-100 μM; 8 hours; PC12 cells) 处理可减轻 OGD 诱导的 PC12 细胞凋亡。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备